AUC | 95% CI | P value | Cut-off | Sensitivity | Specificity | |
Serum NRP-1 | ||||||
Patients with HCC (group I) vs patients with liver cirrhosis (group II) | 0.801 | 0.709 to 0.875 | <0.001* | >1418 | 72.0 | 87.8 |
Patients with HCC (group I) vs healthy controls (group III) | 0.992 | 0.949 to 1.000 | <0.001* | >367 | 96.0 | 98.0 |
Serum ANG-2 | ||||||
Patients with HCC (group I) vs patients with liver cirrhosis (group II) | 0.748 | 0.651 to 0.830 | <0.001* | >2780 | 60.0 | 73.5 |
Patients with HCC (group I) vs healthy controls (group III) | 0.809 | 0.719 to 0.881 | <0.001* | >2679 | 66.0 | 84.0 |
Serum AFP | ||||||
Patients with HCC (group I) vs patients with liver cirrhosis (group II) | 0.762 | 0.666 to 0.842 | <0.001* | >188.0 | 74.0 | 75.5 |
Patients with HCC (group I) vs healthy controls (group III) | 0.983 | 0.934 to 0.998 | <0.001* | >7.9 | 96.0 | 90.0 |
Combined analysis (serum NRP-1+AFP) | ||||||
Patients with HCC (group I) vs patients with liver cirrhosis (group II) | 0.825 | 0.736 to 0.894 | <0.001* | – | 64.0 | 100.0 |
Patients with HCC (group I) vs healthy controls (group III) | 0.994 | 0.952 to 1.000 | <0.001* | – | 96.0 | 100.0 |
*P<0.05 significant.
AFP, alpha-fetoprotein; ANG-2, angiopoietin-2; AUC, area under the curve; HCC, hepatocellular carcinoma; NRP-1, neuropilin-1; ROC, receiver operating characteristic.